Kestra Private Wealth Services LLC Has $1.01 Million Stock Holdings in Kenvue Inc. (NYSE:KVUE)

Kestra Private Wealth Services LLC trimmed its stake in Kenvue Inc. (NYSE:KVUE) by 5.9% in the fourth quarter, HoldingsChannel reports. The firm owned 47,376 shares of the company’s stock after selling 2,953 shares during the period. Kestra Private Wealth Services LLC’s holdings in Kenvue were worth $1,011,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Grove Bank & Trust grew its holdings in shares of Kenvue by 438.4% during the fourth quarter. Grove Bank & Trust now owns 1,163 shares of the company’s stock valued at $25,000 after buying an additional 947 shares during the last quarter. Riverview Trust Co acquired a new position in shares of Kenvue during the third quarter valued at about $30,000. Geneos Wealth Management Inc. acquired a new position in shares of Kenvue during the fourth quarter valued at about $29,000. Ashton Thomas Securities LLC acquired a new position in shares of Kenvue during the third quarter valued at about $35,000. Finally, Fortitude Family Office LLC grew its holdings in shares of Kenvue by 106.6% during the fourth quarter. Fortitude Family Office LLC now owns 1,506 shares of the company’s stock valued at $32,000 after buying an additional 777 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the stock. Deutsche Bank Aktiengesellschaft lowered shares of Kenvue from a “buy” rating to a “hold” rating and dropped their price target for the company from $25.00 to $24.00 in a research report on Thursday, December 12th. Barclays dropped their price target on shares of Kenvue from $23.00 to $21.00 and set an “equal weight” rating on the stock in a research report on Friday, January 17th. Piper Sandler raised shares of Kenvue from a “neutral” rating to an “overweight” rating and raised their price target for the company from $21.00 to $26.00 in a research report on Monday, January 6th. Canaccord Genuity Group dropped their price target on shares of Kenvue from $27.00 to $24.00 and set a “buy” rating on the stock in a research report on Friday, February 7th. Finally, Bank of America raised their price target on shares of Kenvue from $24.00 to $27.00 and gave the company a “buy” rating in a research report on Tuesday, October 22nd. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, Kenvue presently has a consensus rating of “Hold” and a consensus target price of $23.00.

Kenvue Stock Performance

NYSE KVUE opened at $21.47 on Friday. The company’s 50 day moving average is $21.37 and its 200-day moving average is $22.03. Kenvue Inc. has a 12-month low of $17.67 and a 12-month high of $24.46. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. The firm has a market cap of $41.15 billion, a P/E ratio of 40.50, a price-to-earnings-growth ratio of 2.16 and a beta of 1.45.

Kenvue (NYSE:KVUE) last posted its quarterly earnings results on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. Sell-side analysts predict that Kenvue Inc. will post 1.05 earnings per share for the current year.

Kenvue Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, February 26th. Stockholders of record on Wednesday, February 12th will be given a $0.205 dividend. This represents a $0.82 annualized dividend and a dividend yield of 3.82%. The ex-dividend date is Wednesday, February 12th. Kenvue’s dividend payout ratio (DPR) is currently 154.72%.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.